Randle RW, Balentine CJ, Leverson GE, Havlena JA, Sippel RS, Schneider DF, Pitt SC (2017) Trends in the presentation, treatment, and survival of patients with medullary thyroid cancer over the past 30 years Surgery 161:137–146. https://doi.org/10.1016/j.surg.2016.04.053

Le MK, Kawai M, Odate T, Vuong HG, Oishi N, Kondo T (2022) Metastatic Risk Stratification of 2526 Medullary Thyroid Carcinoma Patients: A Study Based on Surveillance, Epidemiology, and End Results Database Endocr Pathol 33:348-358. https://doi.org/10.1007/s12022-022-09724-2

Article  PubMed  Google Scholar 

Xu B, Fuchs TL, Ahmadi S, Alghamdi M, Alzumaili B, Bani MA, Baudin E, Chou A, De Leo A, Fagin JA, Ganly I, Glover A, Hartl D, Kanaan C, Khneisser P, Najdawi F, Nigam A, Papachristos A, Repaci A, Spanheimer PM, Solaroli E, Untch BR, Barletta JA, Tallini G, Al Ghuzlan A, Gill AJ, Ghossein RA (2022) International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma J Clin Oncol 40:96-104. https://doi.org/10.1200/JCO.21.01329

Article  PubMed  Google Scholar 

Vissio E, Maletta F, Fissore J, Osella Abate S, Retta F, Brizzi MP, Piovesan A, Rossetto Giaccherino R, Volante M, Papotti M (2022) External Validation of Three Available Grading Systems for Medullary Thyroid Carcinoma in a Single Institution Cohort Endocr Pathol 33:359-370. https://doi.org/10.1007/s12022-022-09719-z

Article  PubMed  Google Scholar 

Baloch ZW, Asa SL, Barletta JA, Ghossein RA, Juhlin CC, Jung CK, LiVolsi VA, Papotti MG, Sobrinho-Simoes M, Tallini G, Mete O (2022) Overview of the 2022 WHO Classification of Thyroid Neoplasms Endocr Pathol 33:27-63. https://doi.org/10.1007/s12022-022-09707-3

Article  PubMed  Google Scholar 

Ciampi R, Romei C, Ramone T, Prete A, Tacito A, Cappagli V, Bottici V, Viola D, Torregrossa L, Ugolini C, Basolo F, Elisei R (2019) Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing iScience 20:324-336. https://doi.org/10.1016/j.isci.2019.09.030

Article  CAS  Google Scholar 

Xu B, Viswanathan K, Ahadi MS, Ahmadi S, Alzumaili B, Bani MA, Baudin E, Behrman DB, Capelletti M, Chau NG, Chiarucci F, Chou A, Clifton-Bligh R, Coluccelli S, de Biase D, De Leo A, Dogan S, Fagin JA, Fuchs TL, Glover AR, Hadoux J, Lacroix L, Lamartina L, Lubin DJ, Luxford C, Magliocca K, Maloberti T, Mohanty AS, Najdawi F, Nigam A, Papachristos AJ, Repaci A, Robinson B, Scoazec JY, Shi Q, Sidhu S, Solaroli E, Sywak M, Tuttle RM, Untch B, Barletta JA, Al Ghuzlan A, Gill AJ, Ghossein R, Tallini G, Ganly I (2024) Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study Thyroid 34:167-176. https://doi.org/10.1089/thy.2023.0279

Article  CAS  PubMed  Google Scholar 

Censi S, Galuppini F, Clausi C, Battheu F, Manso J, Piva I, Corvaglia S, Pedron MC, Mondin A, Iacobone M, Torresan F, Merante Boschin I, Bertazza L, Barollo S, Pennelli G, Mian C (2024) Tumor Grade and Molecular Characteristics Associated with Survival in Sporadic Medullary Thyroid Carcinoma Thyroid 34:177-185. https://doi.org/10.1089/thy.2023.0482

Article  CAS  PubMed  Google Scholar 

Maliszewska A, Leandro-Garcia LJ, Castelblanco E, Macia A, de Cubas A, Gomez-Lopez G, Inglada-Perez L, Alvarez-Escola C, De la Vega L, Leton R, Gomez-Grana A, Landa I, Cascon A, Rodriguez-Antona C, Borrego S, Zane M, Schiavi F, Merante-Boschin I, Pelizzo MR, Pisano DG, Opocher G, Matias-Guiu X, Encinas M, Robledo M (2013) Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions Am J Pathol 182:350-362. https://doi.org/10.1016/j.ajpath.2012.10.025

Article  CAS  PubMed  Google Scholar 

Mancikova V, Montero-Conde C, Perales-Paton J, Fernandez A, Santacana M, Jodkowska K, Inglada-Perez L, Castelblanco E, Borrego S, Encinas M, Matias-Guiu X, Fraga M, Robledo M (2017) Multilayer OMIC Data in Medullary Thyroid Carcinoma Identifies the STAT3 Pathway as a Potential Therapeutic Target in RET(M918T) Tumors Clin Cancer Res 23:1334–1345. https://doi.org/10.1158/1078-0432.CCR-16-0947

Qu N, Shi X, Zhao JJ, Guan H, Zhang TT, Wen SS, Liao T, Hu JQ, Liu WY, Wang YL, Huang S, Shi RL, Wang Y, Ji QH (2020) Genomic and Transcriptomic Characterization of Sporadic Medullary Thyroid Carcinoma Thyroid 30:1025-1036. https://doi.org/10.1089/thy.2019.0531

Article  CAS  PubMed  Google Scholar 

Koperek O, Scheuba C, Cherenko M, Neuhold N, De Micco C, Schmid KW, Niederle B, Kaserer K (2008) Desmoplasia in medullary thyroid carcinoma: a reliable indicator of metastatic potential Histopathology 52:623-630. https://doi.org/10.1111/j.1365-2559.2008.03002.x

Article  CAS  PubMed  Google Scholar 

NanoString. nCounter® Tumor Signaling 360 panel. . https://nanostring.com/products/ncounter-assays-panels/oncology/tumor-signaling-360/. Accessed February 9, 2024 2024

Rojo F, Corassa M, Mavroudis D, Oz AB, Biesma B, Brcic L, Pauwels P, Sailer V, Gosney J, Miljkovic D, Hader C, Wu M, Almarez T, Penault-Llorca F (2020) International real-world study of DLL3 expression in patients with small cell lung cancer Lung Cancer 147:237–243. https://doi.org/10.1016/j.lungcan.2020.07.026

Mansfield AS, Hong DS, Hann CL, Farago AF, Beltran H, Waqar SN, Hendifar AE, Anthony LB, Taylor MH, Bryce AH, Tagawa ST, Lewis K, Niu J, Chung CH, Cleary JM, Rossi M, Ludwig C, Valenzuela R, Luo Y, Aggarwal R (2021) A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors NPJ Precis Oncol 5:74. https://doi.org/10.1038/s41698-021-00214-y

Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K (2019) DLL3: an emerging target in small cell lung cancer J Hematol Oncol 12:61. https://doi.org/10.1186/s13045-019-0745-2

Gomaa W, Marouf A, Alamoudi A, Al-Maghrabi J (2020) SOX2 Is a Potential Novel Marker of Undifferentiated Thyroid Carcinomas Cureus 12:e12102. https://doi.org/10.7759/cureus.12102

Henke RM, Meredith DM, Borromeo MD, Savage TK, Johnson JE (2009) Ascl1 and Neurog2 form novel complexes and regulate Delta-like3 (Dll3) expression in the neural tube Dev Biol 328:529–540. https://doi.org/10.1016/j.ydbio.2009.01.007

Rudin CM, Poirier JT, Byers LA, Dive C, Dowlati A, George J, Heymach JV, Johnson JE, Lehman JM, MacPherson D, Massion PP, Minna JD, Oliver TG, Quaranta V, Sage J, Thomas RK, Vakoc CR, Gazdar AF (2019) Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data Nat Rev Cancer 19:289-297. https://doi.org/10.1038/s41568-019-0133-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ireland AS, Micinski AM, Kastner DW, Guo B, Wait SJ, Spainhower KB, Conley CC, Chen OS, Guthrie MR, Soltero D, Qiao Y, Huang X, Tarapcsak S, Devarakonda S, Chalishazar MD, Gertz J, Moser JC, Marth G, Puri S, Witt BL, Spike BT, Oliver TG (2020) MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate Cancer Cell 38:60-78 e12. https://doi.org/10.1016/j.ccell.2020.05.001

Article  CAS  Google Scholar 

Strocchi S, Reggiani F, Gobbi G, Ciarrocchi A, Sancisi V (2022) The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation Oncogene 41:3665-3679. https://doi.org/10.1038/s41388-022-02378-8

Article  CAS  PubMed  Google Scholar 

Li S, Rodriguez J, Li W, Bullova P, Fell SM, Surova O, Westerlund I, Topcic D, Bergsland M, Stenman A, Muhr J, Nister M, Holmberg J, Juhlin CC, Larsson C, von Kriegsheim A, Kaelin WG, Jr., Schlisio S (2019) EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance Proc Natl Acad Sci U S A 116:16997–17006. https://doi.org/10.1073/pnas.1900748116

Rodriguez J, Herrero A, Li S, Rauch N, Quintanilla A, Wynne K, Krstic A, Acosta JC, Taylor C, Schlisio S, von Kriegsheim A (2018) PHD3 Regulates p53 Protein Stability by Hydroxylating Proline 359 Cell Rep 24:1316–1329. https://doi.org/10.1016/j.celrep.2018.06.108

Tanaka T, Torigoe T, Hirohashi Y, Sato E, Honma I, Kitamura H, Masumori N, Tsukamoto T, Sato N (2014) Hypoxia-inducible factor (HIF)-independent expression mechanism and novel function of HIF prolyl hydroxylase-3 in renal cell carcinoma J Cancer Res Clin Oncol 140:503–513. https://doi.org/10.1007/s00432-014-1593-7

Andersen S, Donnem T, Stenvold H, Al-Saad S, Al-Shibli K, Busund LT, Bremnes RM (2011) Overexpression of the HIF hydroxylases PHD1, PHD2, PHD3 and FIH are individually and collectively unfavorable prognosticators for NSCLC survival PLoS One 6:e23847. https://doi.org/10.1371/journal.pone.0023847

Dopeso H, Jiao HK, Cuesta AM, Henze AT, Jurida L, Kracht M, Acker-Palmer A, Garvalov BK, Acker T (2018) PHD3 Controls Lung Cancer Metastasis and Resistance to EGFR Inhibitors through TGFalpha Cancer Res 78:1805–1819. https://doi.org/10.1158/0008-5472.CAN-17-1346

Ivan M, Kaelin WG, Jr. (2017) The EGLN-HIF O(2)-Sensing System: Multiple Inputs and Feedbacks Mol Cell 66:772–779. https://doi.org/10.1016/j.molcel.2017.06.002

Lodewijk L, van Diest P, van der Groep P, Ter Hoeve N, Schepers A, Morreau J, Bonenkamp J, van Engen-van Grunsven A, Kruijff S, van Hemel B, Links T, Nieveen van Dijkum E, van Eeden S, Valk G, Borel Rinkes I, Vriens M (2017) Expression of HIF-1alpha in medullary thyroid cancer identifies a subgroup with poor prognosis Oncotarget 8:28650–28659. https://doi.org/10.18632/oncotarget.15622

Jiang A, Zhou Y, Gong W, Pan X, Gan X, Wu Z, Liu B, Qu L, Wang L (2022) CCNA2 as an Immunological Biomarker Encompassing Tumor Microenvironment and Therapeutic Response in Multiple Cancer Types Oxid Med Cell Longev 2022:5910575. https://doi.org/10.1155/2022/5910575

Barger CJ, Branick C, Chee L, Karpf AR (2019) Pan-Cancer Analyses Reveal Genomic Features of FOXM1 Overexpression in Cancer Cancers (Basel) 11. https://doi.org/10.3390/cancers11020251

Hao Z, Zhang H, Cowell J (2012) Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker Tumour Biol 33:723–730. https://doi.org/10.1007/s13277-011-0291-1

Xiang C, Yan HC (2022) Ubiquitin conjugating enzyme E2 C (UBE2C) may play a dual role involved in the progression of thyroid carcinoma Cell Death Discov 8:130. https://doi.org/10.1038/s41420-022-00935-4

Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors Cell 126:663-676. https://doi.org/10.1016/j.cell.2006.07.024

Article  CAS  PubMed  Google Scholar 

Novak D, Huser L, Elton JJ, Umansky V, Altevogt P, Utikal J (2020) SOX2 in development and cancer biology Semin Cancer Biol 67:74–82. https://doi.org/10.1016/j.semcancer.2019.08.007

Wang S, Liu X, Chen Y, Zhan X, Wu T, Chen B, Sun G, Yan S, Xu L (2020) The role of SOX2 overexpression in prognosis of patients with solid tumors: A meta-analysis and system review Medicine (Baltimore) 99:e19604. https://doi.org/10.1097/MD.0000000000019604

Gauchotte G, Philippe C, Lacomme S, Leotard B, Wissler MP, Allou L, Toussaint B, Klein M, Vignaud JM, Bressenot A (2011) BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis Pathology 43:447–452. https://doi.org/10.1097/PAT.0b013e3283486178

Marshall OJ, Marshall AT, Choo KH (2008) Three-dimensional localization of CENP-A suggests a complex higher order structure of centromeric chromatin J Cell Biol 183:1193-1202. https://doi.org/10.1083/jcb.200804078

Article  CAS  PubMed  PubMed Central  Google Scholar 

Roulland Y, Ouararhni K, Naidenov M, Ramos L, Shuaib M, Syed SH, Lone IN, Boopathi R, Fontaine E, Papai G, Tachiwana H, Gautier T, Skoufias D, Padmanabhan K, Bednar J, Kurumizaka H, Schultz P, Angelov D, Hamiche A, Dimitrov S (2016) The Flexible Ends of CENP-A Nucleosome Are Required for Mitotic Fidelity Mol Cell 63:674-685. https://doi.org/10.1016/j.molcel.2016.06.023

Article  CAS  PubMed  Google Scholar 

Liverani C, Bongiovanni A, Mercatali L, Pieri F, Spadazzi C, Miserocchi G, Di Menna G, Foca F, Ravaioli S, De Vita A, Cocchi C, Rossi G, Recine F, Ibrahim T (2021) Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms Endocr Pathol 32:309–317. https://doi.org/10.1007/s12022-020-09657-8

Borromeo MD, Savage TK, Kollipara RK, He M, Augustyn A, Osborne JK, Girard L, Minna JD, Gazdar AF, Cobb MH, Johnson JE (2016) ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs Cell Rep 16:1259–1272. https://doi.org/10.1016/j.celrep.2016.06.081

Niederle MB, Riss P, Selberherr A, Koperek O, Kaserer K, Niederle B, Scheuba C (2021) Omission of lateral lymph node dissection in medullary thyroid cancer without a desmoplastic stromal reaction Br J Surg 108:174-181. https://doi.org/10.1093/bjs/znaa047

Article  CAS  PubMed  Google Scholar 

Gomez-Ramirez J, Luengo P, Mercader E, Quintana A, Munoz de Nova JL, Febrero B, Ruz-Caracuel I, Rodriguez JM (2023) Desmoplastic reaction in medullary thyroid carcinoma predicts presence of lymph node metastasis Br J Surg 110:1011-1012. https://doi.org/10.1093/bjs/znad172

Article  PubMed  Google Scholar 

Ingenwerth M, Brandenburg T, Fuhrer-Sakel D, Goetz M, Weber F, Dralle H, Schildhaus HU, Schmid KW, Theurer S (2021) DLL3 (delta-like protein 3) expression correlates with stromal desmoplasia and lymph node metastases in medullary thyroid carcinomas Endocr Connect 10:283–289. https://doi.org/10.1530/EC-20-0611

Rudin CM, Reck M, Johnson ML, Blackhall